Zentiva
Zentiva is a Czech-headquartered pharmaceutical company focused on generic and over-the-counter medicines.
Last updated August 31, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Zentiva is a pharmaceutical company headquartered in Prague, Czech Republic, with a business centered on developing, manufacturing and marketing generic prescription medicines and over-the-counter products. Its commercial role is to provide lower-cost alternatives to branded medicines across European and selected international markets. The company operates through a portfolio of medicines spanning multiple therapeutic areas, while also maintaining manufacturing capabilities and local commercial organizations in several countries. The business has unusually deep historical roots. Its institutional ancestry is linked to the At the Black Eagle pharmacy in central Prague, documented from 1488. The pharmacy was acquired by the Fragner family in 1857, and successive generations expanded the pharmaceutical activity. A modern factory bearing the Benjamin Fragner name began producing medicines in Prague in 1930. The site later became the core of the company's industrial and research identity and remains associated with Zentiva's Prague operations. During the Second World War, the factory served as a refuge for pharmaceutical specialists after the closure of Czech universities under Nazi occupation. The site was also associated with an early successful isolation of penicillin in Czechoslovakia. Following nationalisation in 1946, the pharmacy and factory were separated and the factory became part of SPOFA, the state pharmaceutical group. Production facilities were upgraded over subsequent decades, including a major modernization completed in 1979. After the Velvet Revolution, the company underwent a sequence of legal, managerial and ownership changes. The business adopted the Zentiva name in the 1990s and shifted toward branded generics, meaning medicines marketed under recognizable product names while using active ingredients whose original exclusivity had expired. Zentiva expanded beyond the Czech market through acquisitions and regional growth. Slovakofarma was added in 2003, followed by Romania's Sicomed in 2005 and Turkey's Eczacibaşi Generic Pharmaceuticals in 2007. The company also entered additional Central and Eastern European markets, including Poland and Russia. Zentiva was listed on the Prague and London stock exchanges in 2004 before becoming part of Sanofi in 2008. Under Sanofi, it served as the group's European generics platform. In 2018, Advent International acquired Zentiva from Sanofi and established it as an independent pharmaceutical business. Under private-equity ownership, Zentiva pursued further expansion in generics, consumer healthcare and manufacturing. It acquired the UK company Creo Pharmaceuticals in 2019, bought Romania-based Solacium Pharmaceuticals the same year, and expanded its industrial footprint through transactions involving an Ankleshwar manufacturing site in India. It also agreed to acquire Alvogen's Central and Eastern European business, completing that transaction in 2020. The company is described as employing more than 4,700 people and operating three manufacturing sites in Prague, Bucharest and Ankleshwar. Its positioning combines broad access to affordable medicines with regional manufacturing and distribution capabilities. Zentiva is therefore best classified as a pharmaceutical corporate brand rather than a UK food brand. Its present identity is that of an independent European generics and over-the-counter medicines group, supported by a long-established Czech manufacturing base and a portfolio assembled through organic development and acquisitions.
History
Zentiva's historical lineage reaches back to the At the Black Eagle pharmacy in Prague, whose origins are documented to 1488. Benjamin and Karel Fragner acquired the pharmacy in 1857. Their descendants developed the enterprise further, and Dr. Jiří Fragner, working with his brother Jaroslav Fragner, established a modern pharmaceutical factory in Prague's Dolní Měcholupy district. The Benjamin Fragner factory began production in August 1930 and became the foundation of the modern Zentiva site. The factory developed research and manufacturing capabilities around active pharmaceutical ingredients and finished medicines. During the Second World War, the closure of Czech universities made the facility an important refuge for specialists. The site was associated with an early successful isolation of penicillin, marketed as BF Mykoin 510. In 1946, the Czechoslovak government nationalised the enterprise and separated the pharmacy from the factory. The factory became part of SPOFA, or United Pharmaceutical Enterprises, and was one of the leading pharmaceutical production sites in post-war Czechoslovakia. Growing demand for pharmaceutical dosage forms led to plans for major capacity and facility improvements during the 1960s. A modernization programme was completed in 1979, adding newer production facilities. After the Velvet Revolution of 1989, the enterprise entered a period of privatization, restructuring and changing corporate identities. In 1993, the company changed its name from Léčiva to Zentiva. In 1998, management acquired a majority shareholding and redirected the business toward branded generic medicines. The Zentiva CZ corporate identity was introduced in 2003. Regional expansion accelerated in the 2000s. Zentiva added Slovakofarma in 2003 and acquired Romania's Sicomed in 2005. In 2007, it acquired Eczacibaşi Generic Pharmaceuticals in Turkey. The company also expanded into Poland, Russia and other Central and Eastern European markets. Zentiva was listed on the Prague and London stock exchanges in 2004. Sanofi acquired Zentiva in 2008 and used it as the European platform for its generics business. Advent International acquired Zentiva from Sanofi in 2018. The transaction restored Zentiva as an independent company and initiated a new phase of acquisition-led growth. In 2019, Zentiva acquired Creo Pharmaceuticals in the United Kingdom and Solacium Pharmaceuticals in Romania. It also signed agreements concerning an Ankleshwar manufacturing site in India and Alvogen's Central and Eastern European business. The Alvogen transaction was completed in 2020, while the Indian manufacturing acquisition expanded Zentiva's production network. The company is headquartered at its historic Prague premises and is described as employing more than 4,700 people. Its manufacturing network includes sites in Prague, Bucharest and Ankleshwar. Zentiva's contemporary business combines generic prescription medicines, branded generics and over-the-counter products, with a strategic emphasis on affordability, access and regional scale. The supplied reference material also reports a proposed or stated acquisition by GTCR in April 2026; because that date is later than the presently established historical period and no separate source URL is provided, it requires verification before being treated as a completed transaction.
- 2022
Top Employer recognition
[1]Zentiva received Top Employer recognition in the Czech Republic and Romania.
- 2020
Alvogen Central and Eastern European business acquired
[1]The completed transaction broadened Zentiva's regional generics portfolio and market coverage.
- 2019
Expansion through Creo and Solacium acquisitions
[1]Zentiva acquired Creo Pharmaceuticals in the UK and Solacium Pharmaceuticals in Romania.
- 2018
Advent International acquires Zentiva from Sanofi
[1]Zentiva became an independent pharmaceutical company under Advent International ownership.
- 2008
Acquired by Sanofi
[1]Sanofi acquired Zentiva and incorporated it into its European generics franchise.
- 2007
Eczacibaşi Generic Pharmaceuticals acquired
[1]The acquisition strengthened Zentiva's position in Turkey and expanded its regional generic medicines platform.
- 2005
Sicomed acquired
[1]Zentiva acquired the Romanian generic pharmaceutical company Sicomed, later known as Zentiva SA.
- 2004
Shares listed in Prague and London
[1]Zentiva expanded its public-market presence through listings on the Prague and London stock exchanges.
- 2003
Zentiva corporate identity introduced and Slovakofarma added
[1]The Zentiva CZ corporate brand was introduced, and Slovakofarma became part of the portfolio.
- 1993
Company adopts the Zentiva name
[1]The company changed its name from Léčiva to Zentiva.
Products and positioning
Affordable, accessible generic and over-the-counter medicines supported by European manufacturing, regional commercial operations and a long pharmaceutical heritage.
Prescription pharmaceuticals
Generic prescription medicines
Zentiva's core portfolio consists of medicines containing active ingredients whose original exclusivity has generally expired. These products are developed, manufactured and marketed as affordable alternatives to originator medicines across a range of therapeutic areas. The company uses both locally established brands and regional commercial organizations to distribute prescription products in European markets.
Pharmaceutical brands
Branded generic medicines
A significant part of Zentiva's strategy has been the development of branded generics: off-patent medicines sold under identifiable product names rather than solely by an international nonproprietary name. This approach supports physician, pharmacist and patient recognition while allowing the company to compete on access, supply and price.
Consumer healthcare
Over-the-counter medicines
Zentiva develops and markets non-prescription medicines and consumer healthcare products intended for self-care. The OTC portfolio complements its prescription generics business and gives the company access to pharmacy and direct consumer channels. Specific product names and therapeutic categories are not identified in the supplied reference material.
Pharmaceutical manufacturing
Pharmaceutical manufacturing services and production
Manufacturing is an important part of Zentiva's operating model. The company is described as having production sites in Prague, Bucharest and Ankleshwar. These facilities support the manufacture of finished medicines and help provide supply capacity for Zentiva's European and international portfolio.
Brand decisions
2020
Completion of Alvogen CEE acquisitionM&ABackground
Zentiva sought to consolidate its position in the generics markets of Central and Eastern Europe.
Action taken
Zentiva completed its acquisition of Alvogen's Central and Eastern European business.
Aftermath
The deal expanded the company's regional portfolio and commercial presence.
2019
Zentiva expands through Creo and SolaciumM&ABackground
After becoming independent, Zentiva sought to increase its presence in Western European and Romanian generics and OTC markets.
Action taken
Zentiva acquired Creo Pharmaceuticals in the United Kingdom and Solacium Pharmaceuticals in Romania.
Aftermath
The acquisitions broadened Zentiva's geographic reach and strengthened its generic and consumer healthcare portfolio.
2019
Expansion of manufacturing footprintStrategyBackground
Zentiva was building an independent supply and manufacturing network after its separation from Sanofi.
Action taken
The company signed an agreement concerning a manufacturing site in Ankleshwar, India.
Aftermath
The site became part of Zentiva's described three-site manufacturing network.
2018
Advent International acquires ZentivaM&ABackground
Sanofi decided to sell its European generics business as part of a portfolio and strategic realignment.
Action taken
Advent International acquired Zentiva and made it an independent company.
Aftermath
The transaction enabled Zentiva to pursue independent expansion through acquisitions in generics, OTC medicines and manufacturing.
Reported transaction value. €1.919 billion (2018 acquisition)
2008
Zentiva joins SanofiM&ABackground
Zentiva had expanded across Central and Eastern Europe and was operating as a listed generics company.
Action taken
Sanofi acquired Zentiva and used it as the European platform for its generics business.
Aftermath
Zentiva became part of Sanofi's generics franchise until its subsequent divestment in 2018.
Recent events
- Unconfirmed
Reported
Zentiva completes acquisition of Ankleshwar manufacturing site[2]
Zentiva Group announced that it had completed its acquisition from Sanofi of a manufacturing site in Ankleshwar, India.
Reported
Zentiva completes acquisition of Alvogen’s CEE business[3]
Zentiva Group completed its acquisition of Alvogen’s Central and Eastern European business, including the Labormed site in Bucharest.
Zentiva appoints Kenneth Lynard as provisional director[4]
Zentiva appointed Kenneth Lynard as provisional director effective October 1, following the resignation of Blery Carol Jean Noel.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/zentiva · Editorial policy · How profiles are compiled